Pharma Co. Shares Get a Bang from FDA Orphan Drug Approval
Source: Streetwise Reports  (3/9/22)
Shares of C4 Therapeutics Inc. traded 16% higher after the biopharma company reported that the U.S. FDA granted Orphan Drug approval status for its CFT8634 for use in treating soft tissue sarcoma. More >

Regenerative Medicine Co. Posts 38% Sales Gain in 2021
  (3/2/22)
Organogenesis Holdings Inc. shares traded 23% higher after the company reported FY/21 financial results that included a 46% YoY increase in revenue from its Advanced Wound Care products sales. More >

This Year Should Be Catalyst Rich for Oncology Pharma Co.
  (3/1/22)
An outperform-rated biopharma, which has a robust year of significant events ahead, is trading now at a significant discount, noted a Wedbush report. More >

Biotech to Take Novel Cancer Drug to Market in H1/22
Source: Streetwise Reports  (2/28/22)
This biotech company is commercializing its lead drug candidate, Kimmtrak, has a catalyst-rich 2022, and has various clinical-stage drugs for cancers and autoimmune and infectious diseases. More >

Super Computers Create Powerful Drugs for Alzheimer's
Source: Streetwise Reports  (2/25/22)
A promising biotech company is finding new ways to treat neurodegenerative diseases by focusing on misfolded proteins. More >

Pharma Co. Posts 364% YOY Revenue Increase in Q421
Source: Streetwise Reports  (2/25/22)
Aerie Pharmaceuticals Inc. shares traded 30% higher after the ophthalmology-focused pharmaceutical company reported Q4/21 and FY/21 financial results and announced the appointment of a new Chief Medical Officer. More >

Pharma Co. Decreases BMI by 14.3% in Obesity Trial
Source: Streetwise Reports  (2/18/22)
Shares of this pharmaceutical company traded 16% higher after it reported positive interim data from its long-term extension study of a treatment for obesity and hyperphagia in patients with Bardet-Biedl Syndrome (BBS). More >

Pain Mgt. Co. Makes $604M Bid for BioDelivery Sciences
  (2/14/22)
Shares of BioDelivery Sciences International Inc. traded 52% higher after the company reported that it agreed to be acquired by Collegium Pharmaceutical Inc. in an all-cash deal for $5.60 per share. More >

Canadian Hedge Fund CIO Talks Top 2022 Prospects
Source: Streetwise Reports  (2/9/22)
AlphaNorth Asset Management was recently recognized with multiple performance awards at the 2021 Alternative IQ Canadian Hedge Fund Awards. The AlphaNorth Partners Fund won first place for its five-year annualized return gaining 40.35% for the period. The fund also placed second for its three-year return and third for its one-year return. Streetwise Reports sat down with CIO Steven Palmer to discuss some of the firm's recent investments and emerging opportunities for 2022. More >

Todos COVID-19 Drug Shows Superiority to Remdesivir, Takes Dying Off the Table
Source: Vision and Value  (2/8/22)
In a phase 2 clinical study, Todos Medical's oral antiviral Tollovir showed a 100% reduction in mortality from COVID-19. More >

Investors: Will a Psychedelic Drug Take This Pharma Stock to the Next Level?
Source: Streetwise Reports  (2/7/22)
Algernon Pharmaceuticals plans to be the world's first company to test the psychedelic drug DMT in stroke patients, and it's close to achieving its goal. More >

Drug Re-Purposing Co. Pursues Novel Stroke Therapies
Source: Streetwise Reports  (2/3/22)
Drug re-purposing co. Algernon Pharmaceuticals Inc. is actively reinventing itself. The firm's leading therapeutic candidate NP-120 (Ifenprodil) is currently being evaluated in a Phase 2 trial for IPF and chronic cough, and the company is now moving forward with a revolutionary new use for DMT to treat ischemic stroke. More >

Co. Focused on Pipeline of Drug Candidates
  (1/31/22)
In the clinic, Algernon Pharmaceuticals is advancing Ifenprodil in three indications and DMT in stroke, noted a Research Capital Corp. report. More >

Biopharma Co. to Resubmit BLA to FDA for Type 1 Diabetes
Source: Streetwise Reports  (1/31/22)
Shares of Provention Bio Inc. traded 29% higher after the company reported that following its Type B meeting and conversations with the U.S. FDA, it is now planning to resubmit a Biologics License Application for delay of clinical type 1 diabetes in at-risk individuals. More >

Neuroscientist With Research Program Joins Biotech's SAB
Source: Streetwise Reports  (1/29/22)
ProMIS Neurosciences appointed to its science advisory board Canada-based Dr. Cheryl Wellington, professor, neuroscientist and head of a globally recognized neuro research program. More >

Pharma to Test if DMT Helps Brain Regain Function Post Stroke
Source: Streetwise Reports  (1/28/22)
During Streetwise Live! on Jan. 27, 2022, representatives of Algernon Pharmaceuticals discussed the use of the psychedelic DMT in stroke sufferers. On the broadcast were Algernon CEO Christopher Moreau and consultants to the firm, Dr. David Nutt and Dr. Rick Strassman. More >

Co. Meets Goals in COVID Drug Trial
Source: Streetwise Reports  (1/28/22)
Todos Medical has closed a Phase 2 trial of its antiviral 3CL protease inhibitor Tollovir after getting positive interim data. More >

Possible Treatment for CRC Shows Promise
  (1/25/22)
New trial results of Exelixis' cabozantinib in colorectal cancer are encouraging for further development of the biopharma's XL902 in the indication, noted an H.C. Wainwright & Co. report. More >

Bone Cancer Drug Meets Goals, Stocks Rise
Source: Streetwise Reports  (1/25/22)
Shares of Sierra Oncology Inc. traded 48% higher after the company reported that topline data obtained during its Pivotal Phase 3 MOMENTUM Myelofibrosis Study showed that its momelotinib produced statistically significant improvements in anemia and splenic size. More >

FDA Gives Fast Track Status to Firm for Adrenal Rescue Pen
  (1/24/22)
Now with fast track status and positive Phase 1 study results, Antares Pharma plans to advance its ATRS-1902 product candidate into a second trial in Q2/22, noted a Ladenburg Thalmann report. More >

Fourth COVID-19 Vaccine Shot Shown Less Effective
  (1/24/22)
BioNTech aims to develop a COVID-19 vaccine targeting the Omicron variant, noted an H.C. Wainwright & Co. report. More >

‘Strong Data’ Expected From Todos Medical Data Lock
Source: Vision and Value  (1/24/22)
Todos Medical is set to take on the dominant players in oral antivirals for mild to moderate COVID-19, Pfizer Inc. and Merck & Co. Inc., with "strong data" expected to be released soon for its drug Tollovir. More >

First NSCLC Patient Dosed With Trial Therapeutic
  (1/22/22)
Two recent Vaccitech events, the MAGE trial initial dosing and the acquisition of Avidea's SNAPvax technology, bode well for its ChAdOx1-MVA platform, noted an H.C. Wainwright & Co. report. More >

Fund Triples Holding of Drug Repurposing Firm
Source: Streetwise Reports  (1/20/22)
Several events slated to happen this year could boost Algernon Pharmaceuticals' share price, noted an AlphaNorth Partners Fund performance report. More >

Belgium Firm to Buy Epilepsy-Focused Biopharma Co. for $1.9B
Source: Streetwise Reports  (1/19/22)
Shares of Zogenix Inc. rose by 66% after the company reported it entered into an agreement to be acquired by UCB. S.A. of Belgium for $26.00 per share in cash. The offer includes the potential for an additional $2.00 per share if a specific drug approval milestone is met. More >